Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript

Scholar Rock announced a BLA resubmission for apitegromab in spinal muscular atrophy and discussed regulatory progress on a March 31, 2026 investor call. Management (CEO, President of R&D, COO, CFO) framed the update as forward progress but provided no approval or timelines; this is modestly positive for SRRK and likely to move the stock in the ~1-3% range on investor reaction.

Analysis

Approval of a myostatin-targeting adjunct (apitegromab) would shift the SMA commercial dynamics from a single-class contest (SMN upregulators vs gene therapy) to combination care where incremental functional gains drive payer negotiation. Expect two second-order effects: (1) payers will push for net-pricing constructs (bundles or outcomes-based contracts) when an adjunct duplicates benefit across patients already on high-cost SMN therapy, and (2) infusion/inpatient revenue for clinic-administered comparators could decline if apitegromab is delivered in outpatient or less resource-intensive settings, pressuring service revenue lines for some hospitals over 12–36 months.

Regulatory path risk is binary and timing-sensitive: procedural milestones (60-day filing review, potential Complete Response clarity, or an advisory committee requirement) will compress material moves into defined windows over the next 3–12 months. A favorable approval clears commercial execution risks but converts clinical risk to payer/access risk — expect negotiations with PBMs and national authorities to determine real-world uptake, which can take another 6–18 months and materially cap early revenue.

Competitors with entrenched SMN franchises face margin pressure rather than immediate collapse; incumbents will lean on established distribution and long-term outcomes data, so market share erosion will be gradual, likely 5–25% over 2–5 years depending on label breadth. The biggest underappreciated leverage is combination pricing: if apitegromab is priced as an adjunct, a small absolute improvement in motor outcomes could justify premium pricing and expand addressable population (older, previously untreated patients), which the market is likely underestimating today.

For investors, the highest-conviction outcome is event-driven dispersion between clinical/regulatory binary outcomes and longer-term payer friction. That creates a classic long-biotech, short-duration volatility trade around FDA workstreams, with an explicit hedging overlay for unfavorable regulatory or reimbursement headlines.

Key Decisions for Investors

• Directional LEAP spread on SRRK: Buy SRRK 12–24 month LEAP calls and sell a higher-strike LEAP to fund ~40–60% of premium (ticker SRRK). Thesis: captures approval rerating while capping premium decay; target 3x upside on approval, max loss = net premium. Timeframe: 6–24 months to capture resubmission/acceptance/approval windows.
• Event-driven long equity with payer-risk hedge: Initiate a modest long position in SRRK equity (size 0.5–1% of portfolio) and hedge with a short call or buy protective puts during the 60–120 day FDA review window. Rationale: asymmetric upside at acceptance/approval; downside limited by hedges if FDA signals additional data needs.
• Relative-value pair: Long SRRK / Short Biogen (BIIB) or Roche ADR (RHHBY) over 12 months to express share-shift risk from adjunct approval. Position small (0.5% net exposure) — target spread widening if apitegromab gains label allowing combination use; risk: incumbents’ entrenched prescribing and outcomes data slow conversion.
• Short-dated volatility sell into pop: If SRRK IV crushes post-acceptance, sell short-dated implied volatility (calendar sell or covered calls) around subsequent data/fiscal catalysts to monetize re-rating; keep size limited because binary clinical/regulatory events can gap stock >50% intraday. Timeframe: tactical within 30–90 days after FDA milestones.